their effects on both CDK1 / cyclin B and the K‐562 (human chronic myelogenus leukemia) cell line were evaluated. Using a computational model, we have observed that all the most active compounds 9e, f, i–n exhibited the same binding mode of purvanalol A in the ATP‐binding cleft. Although they were able to moderately inhibit the leukemic cell line K‐562 and to show inhibitory activity against the Cdc2‐Cyclin
已经合成了一系列 N-1H-吲唑-1-甲酰胺,并评估了它们对 CDK1/细胞周期蛋白 B 和 K-562(人慢性粒细胞白血病)细胞系的影响。使用计算模型,我们观察到所有最活跃的化合物 9e、f、i-n 在 ATP 结合裂缝中表现出相同的 purvanalol A 结合模式。尽管它们能够适度抑制白血病细胞系 K-562 并在低微摩尔范围内显示出对 Cdc2-细胞周期蛋白 B 激酶的抑制活性,但结果证明它们对来自人类的 HuDe (IZSL) 原代细胞培养物无细胞毒性。真皮。鉴于上述化合物证明的低毒性,这些初步结果非常令人鼓舞。